» Articles » PMID: 21658248

Bactericidal Activity of Oxacillin and Glycopeptides Against Staphylococcus Aureus in Patients with Endocarditis: Looking for a Relationship Between Tolerance and Outcome

Abstract

Background: There is no clear relationship between in vitro bactericidal activity tests and clinical outcome. We studied bactericidal activity of oxacillin, vancomycin and teicoplanin against Staphylococcus aureus isolates in patients with endocarditis and then we sought to determine if there was a relationship between in vitro bactericidal activity and clinical outcome.

Methods: Minimal bacteriostatic and minimal bactericidal concentrations were determined for Staphylococcus aureus strains isolated from patients with endocarditis following standardized methods. Medical records were reviewed retrospectively to collect data on antimicrobial susceptibility at admission, antimicrobial therapy, need for surgery, embolic events and outcome.

Results And Discussion: Sixty-two Staphylococcus aureus strains were studied in 62 patients with endocarditis. Overall, 91.9% definite, 21% methicillin resistant and 72.6% cured. Surgery was performed in 32.3% and embolic events were documented in 64.5%. Tolerance to oxacillin and teicoplanin was more common than vancomycin tolerance among methicillin susceptible Staphylococcus aureus. Among methicillin resistant Staphylococcus aureus teicoplanin was shown to have a higher rate of tolerance than vancomycin. No statistically significant differences on clinical outcome between oxacillin tolerant and oxacillin non tolerant Staphylococcus aureus infections were observed. Tolerance to oxacillin did not adversely affect clinical outcomes of patients with methicillin susceptible Staphylococcus aureus endocarditis treated with a combination of antimicrobials including oxacillin. The cure rate was significantly lower among patients with methicillin resistant Staphylococcus aureus endocarditis.

Conclusions: In vitro bactericidal test results were not valid predictors of clinical outcome. Physicians need to use additional parameters when treating patients with staphylococcal endocarditis.

Citing Articles

Antibiotic tolerance among clinical isolates: mechanisms, detection, prevalence, and significance.

Deventer A, Stevens C, Stewart A, Hobbs J Clin Microbiol Rev. 2024; 37(4):e0010624.

PMID: 39364999 PMC: 11629620. DOI: 10.1128/cmr.00106-24.


Understanding tolerance to cell wall-active antibiotics.

Dorr T Ann N Y Acad Sci. 2020; 1496(1):35-58.

PMID: 33274447 PMC: 8359209. DOI: 10.1111/nyas.14541.


Combating Antibiotic Tolerance Through Activating Bacterial Metabolism.

Liu Y, Yang K, Zhang H, Jia Y, Wang Z Front Microbiol. 2020; 11:577564.

PMID: 33193198 PMC: 7642520. DOI: 10.3389/fmicb.2020.577564.


An Experimental Framework for Quantifying Bacterial Tolerance.

Brauner A, Shoresh N, Fridman O, Balaban N Biophys J. 2017; 112(12):2664-2671.

PMID: 28636922 PMC: 5479142. DOI: 10.1016/j.bpj.2017.05.014.


Relationship between vancomycin tolerance and clinical outcomes in Staphylococcus aureus bacteraemia.

Britt N, Patel N, Shireman T, El Atrouni W, Horvat R, Steed M J Antimicrob Chemother. 2016; 72(2):535-542.

PMID: 27999028 PMC: 6075607. DOI: 10.1093/jac/dkw453.


References
1.
Sakoulas G, Moise-Broder P, Schentag J, Forrest A, Moellering Jr R, Eliopoulos G . Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004; 42(6):2398-402. PMC: 427878. DOI: 10.1128/JCM.42.6.2398-2402.2004. View

2.
Sabath L, Wheeler N, Laverdiere M, BLAZEVIC D, Wilkinson B . A new type of penicillin resistance of Staphylococcus aureus. Lancet. 1977; 1(8009):443-7. DOI: 10.1016/s0140-6736(77)91941-9. View

3.
Jones R . Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis. 2005; 42 Suppl 1:S13-24. DOI: 10.1086/491710. View

4.
Steinkraus G, White R, Friedrich L . Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother. 2007; 60(4):788-94. DOI: 10.1093/jac/dkm258. View

5.
Charles P, Ward P, Johnson P, Howden B, Grayson M . Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004; 38(3):448-51. DOI: 10.1086/381093. View